Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR17 | Q13304 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 11/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.38 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695442 | 0.97 | GPR17 (0.40) | GPR17AURKAPTK2PDGFRBFGFR1 | |
| SCHEMBL7989412 | 0.87 | MPO (0.39) | AURKAPTK2PDGFRBFGFR1KDR | |
| SCHEMBL6412628 | 0.83 | PTK2 (0.35) | AURKAPTK2NPC1LMNAGAA | |
| SCHEMBL5413673 | 0.82 | KMT2A (0.50) | AURKAKDM4ENPC1LMNAGAA | |
| SCHEMBL3802492 | 0.81 | GAA (0.46) | AURKAPTK2CYP2C19KDM4ENPC1 | |
| SCHEMBL6407392 | 0.81 | ALDH1A1 (0.41) | AURKAPTK2PARP1NPC1LMNA | |
| SCHEMBL6692185 | 0.80 | CDK4 (0.33) | PTK2NPC1LMNAGAAALOX15 | |
| SCHEMBL6613602 | 0.79 | GAA (0.43) | KDM4EPARP1NPC1LMNAGAA | |
| SCHEMBL5410145 | 0.78 | GLA (0.42) | KDM4EPARP1LMNAGAAHTT | |
| SCHEMBL6617381 | 0.78 | KMT2A (0.41) | KDM4ENPC1LMNAGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-7897602-B2 | Indolinone compounds as kinase inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2011-03-01 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2010-07-15 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2004-12-30 | — | — | US | disclosed |
| US-6777417-B2 | ANTICANCER AGENTS | SUGEN, INC. | 2004-08-17 | — | — | US | disclosed |
| EP-1436259-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | Liang, Congxin (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SUGEN, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003022815-A1 | 3-(4,5,6,7-TETRAHYDROINDOL-2-YLMETHYLIDIENE)-2-INDOLINONE DERIVATIVES AS KINASE INHIBITORS | SUGEN, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179146-A1 | Indolinone Compounds as Kinase Inhibitors | CDK2, MAP3K19, MAP3K20 | GPR17 2304/4885AURKA 96/4885PTK2 388/4885 |
| US-20040266855-A1 | 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | GPR17 924/4885AURKA 433/4885PTK2 36/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | GPR17 2012/4885AURKA 299/4885PTK2 261/4885 |
| US-20030119819-A1 | 3-(4,5,6,7-Tetrahydroindol-2-ylmethylidiene-2-indolinone derivatives as kinase inhibitors | SRC, LCK, MAP3K20 | GPR17 869/4885AURKA 409/4885PTK2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.